INTRODUCTION
Measuring changes in radioligand binding caused by fluctuations in synaptic dopamine is at present the only way to draw inference on changes in dopamine concentrations in the living human brain. Reductions in radioligand binding to dopamine D 2/3 receptors measured with positron emission tomography (PET) or single photon emission computer tomography (SPECT) have been shown after several behavioral (Koepp et al, 1998; de la FuenteFernandez et al, 2002; Pruessner et al, 2004; Zald et al, 2004; Volkow et al, 2006) and pharmacological manipulations Volkow et al, 1994; Tedroff et al, 1996; de la Fuente-Fernandez et al, 2004) , which raise endogenous dopamine levels. In particular, the well-replicated finding of greater reductions in [ 11 C]-raclopride and [
123 I]IBZM binding after d-amphetamine administration in patients with schizophrenia when compared to healthy controls (Laruelle et al, 1996 (Laruelle et al, , 1999 Breier et al, 1997; Abi-Dargham et al, 1998) has generated considerable interest in this research strategy. A critical shortcoming of these studies is the ceiling-effect found with conventional antagonist-radiotracers (Laruelle, 2000) , and although competitive inhibition of radioligand binding at the D 2/3 receptor by dopamine is believed to be one of the main mechanisms underlying reductions in radioligandbinding, the exact nature of the process is still not fully elucidated (for review see Ginovart, 2005) .
It is well established in vitro that D 2 receptors exist in two interconvertible affinity states for their natural agonist dopamine, the high-affinity state (D 2 high ; K d for dopamine 1.570.2 nM) and the low-affinity state (D 2 low ; K d for dopamine in the micromolar range; Sibley et al, 1982) . Since D 2 high mediates signal transduction at the postsynaptic neuron, the high-affinity state is believed to be the functionally important one (Zahniser and Molinoff, 1978; George et al, 1985; Leff, 1995) . As a result of the large difference in K d values between D 2  high and D 2   low , under physiological conditions, dopamine is expected to bind to D 2 high only. So far, all D 2/3 radioligands used in human PET or SPECT studies are radio-labelled antagonists, which do not differentiate between D 2 high and D 2 low . Several research groups have recently reported on development and experimental use of newly developed D 2/3 agonist radioligands (Zijlstra et al, 1993a, b; Shi et al, 1999 Shi et al, , 2004 Hwang et al, 2000; Mukherjee et al, 2000 Mukherjee et al, , 2004 Finnema et al, 2005; Narendran et al, 2004) . Similar to dopamine, D 2/3 agonist radioligands are expected to bind mainly to D 2 high . As a consequence, they should be particularly sensitive to competition with endogenous dopamine. This has recently been confirmed in experiments in pigs (Cumming et al, 2003) , rodents (Cumming et al, 2002) , non-human primates (Narendran et al, 2004; Seneca et al, 2006) , and cats .
( + )-4-Propyl-9-hydroxynaphthoxazine, ( + )-(PHNO), is a full agonist at D 2/3 receptors (Brown et al, 1997) . Labelled with carbon-11 (Wilson et al, 2005) , it is a PET ligand with excellent signal-to noise ratio and favorable kinetics for PET imaging in humans Willeit et al, 2006 
MATERIALS AND METHODS

Study Protocol
This study consisted of two parts. Part one was designed to determine test-retest reliability of [ 
Study Subjects and Safety Procedures
This study has been approved by the local Ethics Committee and the Canadian Ministry of Health, Therapeutic Products Research Department. Twenty-three healthy volunteers (nine females, 14 males; mean age: 3379 years, range: 18-49 years) were recruited by advertisements or word of mouth. Written informed consent was obtained after full explanation of study procedures and risks. Routine blood and urine tests, an electrocardiogram (ECG) and a physical exam were performed before inclusion. Psychiatric disorders were assessed using the MINI-Plus structured interview (Sheehan et al, 1998) . Subjects with serious or unstable medical or neurological conditions, axis-one psychiatric diagnoses, substance abuse other than caffeine or nicotine within 6 months before baseline visit were not included into the study. On a day of a PET examination, smokers (n ¼ 5) were asked to consume no more than their usual amount of cigarettes, and all participants were asked to abstain from alcohol intake 24 h before PET scans, and from caffeine-containing beverages 12 h before scans. A standardized light breakfast was served before d-amphetamine/placebo intake.
Standard urine tests for psychotropic substances were performed at inclusion and before PET scans. Pregnancy was excluded using serum HCG analysis at inclusion and standard urine pregnancy tests before each scan. Blood pressure measurements and continuous ECG monitoring were performed during all scans. Participants had a physical exam and standard ECGs immediately after scans. To document safety of [ 11 C]-( + )-PHNO PET procedures, the first 12 subjects underwent an additional physical exam, ECG, routine blood and urine analysis the day after PET scans.
Eleven subjects (one female) completed the test-retest protocol, nine subjects (five females) the d-amphetamine protocol. Three subjects (all females) dropped out during or after the first [
11 C]-( + )-PHNO PET scan (two because of nausea, one subject had moved away).
d-Amphetamine Administration
Two hours before radiotracer injection, participants were administered either two or three capsules containing damphetamine (Dexedrine s tablets, Glaxo Smith Kline, Mississauga, ON) or an equal number of identical capsules containing inactive lactose-powder. Participants and research personnel were blind to the content of the capsules. According to body weight, 25, 30, or 35 mg d-amphetamine were administered, resulting in a dose of 0.38-0.45 mg/kg body weight (mean7SD dose: 27.873.02 mg; mean7SD dose per kg body weight: 0.4270.02 mg). Five millilitres of blood were drawn immediately before PET scans, centrifuged, and stored at À801C for determination of serum d-amphetamine levels.
Subjective drug effects were measured using the Drug Effects Questionnaire (DEQ; Justice and de Wit, 2000) and stimulant-subscales of the Subjective States Questionnaire (SSQ; White et al, 2002) . Both scales are visual analog-scales previously shown to be sensitive to d-amphetamine effects (Justice and de Wit, 2000; White et al, 2002) . Scales were administered before d-amphetamine/placebo intake and 60 and 230 min thereafter. Heart rate and blood pressure were measured at 15, 30, 60, 90, and 180 min after d-amphetamine administration, after tracer injection, and after PET scans. 11 C]-( + )-PHNO has been described in detail elsewhere (Wilson et al, 2005 
Image Acquisition
All PET images were acquired on a CPS-HRRT highresolution neuro-PET camera system (Siemens Medical Imaging, Knoxville, TN) with an in-plane resolution of approximately 2.8 mm full-width at half-maximum (FWHM). Participants were scanned in supine position using a custom-made thermoplastic facemask together with a head-fixation system (Tru-Scan Imaging, Annapolis). Transmission scans were acquired before emission scans using a single photon point source, 137 Cs (T ¼ 30.2 years, Eg ¼ 662 keV) and used for attenuation correction. A saline solution of 355.2744 MBq [
11 C]-( + )-PHNO with a specific activity at time of injection of 42.65713.2 GBq/mmol was injected as a bolus into an intravenous line placed in an antecubital vein. The line was flushed with 10 ml saline immediately after tracer injection and subsequently removed. Emission data were acquired in list mode over 90 min, raw data were reconstructed by filtered-back projection to yield dynamic images with 15 1-min frames and 15 5-min frames. Proton-density (PD) magnetic resonance images (MRIs) were obtained on a General Electric Medical System Signa 1.5T MRI scanner (General Electric Medical Systems, Milwaukee, WI).
Image Analysis
All PET images were analyzed using the in-house automated image analysis software ROMI. Exact procedures used in ROMI are described elsewhere (Rusjan et al, 2006a) . In brief, a PD-MRI template in Montreal Neurologic Institute/ International Consortium for Brain Mapping (MNI/ICBM) standard brain space was co-registered to PD-MRI images using nonlinear iterative co-registration algorithms implemented in SPM2 (http://www.fil.ion.ucl.ac.uk/spm/). Transformation matrices were then applied to a standardized template in MNI/ICBM space containing predefined regions of interest (ROIs) for caudate (CAU), putamen (PUT), ventral striatum (VST), globus pallidus (GP), and cortical cerebellum (CER). Definition of the VST in the template followed the method of Mawlawi et al (2001) . After spatial co-registration to PD-MRIs, the template was refined using gray matter probability-maps obtained from MRIs using SPM2. Since GP is imaged with a tone halfway between gray and white matter structures, a special algorithm using a predefined volume for GP (Spinks et al, 2005) was applied to refine the GP-ROI . PD-MRIs were co-registered to summed PET images, the spatial transformation matrix was then applied to the refined ROIs. Data from both hemispheres were pooled to obtain average radioactivity concentrations in the volumes of interest. Regional radioactivity was determined for each frame, corrected for decay, and plotted vs time to obtain timeactivity curves (TACs). The simplified reference tissue model (SRTM; Lammertsma et al, 1996) was applied to derive binding potentials (BPs) for each region of interest using PMOD software (Version 2.6.1; PMOD Technologies Ltd, Zurich, Switzerland). Cortical cerebellum served as reference region since it is virtually devoid of dopamine D 2 and D 3 receptors in humans (Camps et al, 1989; Hall et al, 1996; Levant, 1998) . The use of the SRTM with a cerebellar input function has recently been validated using kinetic modelling and shown to provide adequate quantification of D 2/3 receptors with [
11 C]-( + )-PHNO in humans .
To validate the automated image analysis software for [
11 C]-( + )-PHNO, 12 PET scans of six participants were analyzed using ROMI software and in a conventional manual way. For manual analysis, MRI scans were coregistered to PET scans using Analyze 5.0 software (Biomedical Imaging Resource, Mayo Clinic, Rochester, MN). Regions of Interest for CAU, PUT, VST, GP, and CER were drawn on PD-MRI images and subsequently transferred onto PET images. Typically, five axial PET slices were used for CER (around the outermost border of cerebellar cortex, sparing midline structures), 7-8 axial slices for CAU and PUT, and 6-7 axial slices for GP. Delineation of the VST followed the method described by Mawlawi et al (2001) .
For an analysis of d-amphetamine effects without a priori anatomical hypothesis, parametric maps of d-amphetamine and placebo scans were constructed using PMOD software and subsequently analyzed using SPM2. For each scan, the SRTM was applied voxelwise using CER as reference region to create parametric maps with a voxel size of 2 Â 2 Â 2 mm (x-y-z). A template was constructed using a mean image of naïve BP maps. Individual parametric maps were spatially normalized to the template by Nearest Neighbor interpolation algorithm. Effects of d-amphetamine administration were assessed voxel-wise using paired t-test procedures implemented in SPM2.
Statistical Analysis
Differences in the magnitude of change between placebo and d-amphetamine and between scan one and scan two in d-amphetamine/placebo and test/re-test parts of the study were analyzed using repeated measures analysis of variance (RM-ANOVA). Binding potentials in the four ROIs were the dependent variables, the repetition factor was termed 'condition' (ie, d-amphetamine vs placebo and scan one vs scan two). The respective study part (d-amphetamine/ placebo vs test/retest) was the between-subject variable. The significance of the 'study part*condition' interactions are reported. Paired-samples t-tests (two-tailed) were used for post hoc comparisons. Correlations between d-amphetamine plasma levels and d-amphetamine-induced reductions in [ All tests were performed using the statistical software package SPSS, Release 12.0.1 (SPSS Inc., Chicago, IL).
RESULTS
Physiological Effects/Safety of [ 11 C]-( + )-PHNO
Injection of [ 11 C]-( + )-PHNO did not lead to any significant changes in blood pressure, heart rate, or ECG at any time in the study. Similarly, there were no relevant findings in physical or neurological exams or in routine blood and urine analyses during the study. However, as described previously (Willeit et al, 2006) , participants described mild and self-limited (duration 2-3 min) side effects (slight nausea or abdominal sensations of warmth) in one-third of the scans (14 of 43 scans). One subject wished to interrupt the scan; another one had a single episode of vomiting and did not reassume scanning thereafter because of data loss. Full data sets were acquired in 20 subjects.
Physiological and Subjective Effects of d-Amphetamine Administration
In good agreement with previous data [http://us.gsk. com/products/assets/us_dexedrine.pdf], administration of d-amphetamine resulted in serum levels of 53.2724.4 ng/ml (range: 11.6-73.8 ng/ml) two hours post d-amphetamine intake (p.i.), that is, immediately before the PET scan. There was a significant increase in systolic (baseline: 115712 mm Hg; peak 90 min p.i.: 132723 mm Hg) and diastolic (baseline: 7377 mm Hg; peak 60 min p.i.: 77713 mm Hg) blood pressure and in DEQ-ratings (baseline: 5.271.8; 60 min p.i.: 6.672.6; 230 min p.i.: 8.378.4) after damphetamine intake. Heart rate and SSQ did not differ significantly between conditions.
Imaging Results
Binding potentials obtained with the automated image analysis software ROMI and conventional manual analysis showed excellent correlations in all investigated ROIs: CAU: r ¼ 0.973, po0.001; PUT: r ¼ 0.993, po0.001; VST: r ¼ 0.966, po0.001; GP: r ¼ 0.916, po0.001.
Indicating a lack of blood-flow effects on the free and non-specific tracer compartment, TACs obtained in d-amphetamine and placebo scans for the reference region CER were congruent ( Figure 1 ). As described in detail elsewhere Willeit et al, 2006) , tracer 
Binding Potential Maps
Overall appearance of parametric BP maps was similar to summated [ (Figure 2 ), a brain region that is particularly sensitive for the actions of psychostimulants and critical for their reinforcing properties (Di Chiara, 1999; Kiyatkin and Brown, 2003; Wise, 2004; Sellings et al, 2006) . This result was confirmed in a voxel-wise analysis of parametric BP maps. The specificity of the measured signal-change is supported by significant correlations between changes in [ (Figure 1) show that changes in free and non-specific tracer compartments did not contribute significantly to the findings.
This being the first study on D 2/3 agonist displacement in humans, the present results will be discussed in light of human experiments using D 2/3 antagonist radioligands and data employing agonist radioligands in animals. Several studies have examined the effect of d-amphetamine administration on D 2/3 antagonist radioligand binding in humans (Breier et al, 1997; Farde et al, 1992; Laruelle et al, 1995; AbiDargham et al, 1998; Cardenas et al, 2004; Riccardi et al, 2006) . Owing to methodological differences such as damphetamine administration route (most studies used intravenous d-amphetamine administration), tracer administration (eg bolus vs bolus/constant infusion), control 
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conditions (placebo vs no intervention), ROI delineation and differences in scanner equipment and sample composition, results of these studies are not directly comparable to the present ones. However, reductions compared to baseline described after similar doses of d-amphetamine and similar post-intake scanning intervals lie generally between approximately 10 and 15% for the whole striatum (Breier et al, 1997; Cardenas et al, 2004; Farde et al, 1992; Laruelle et al, 1997; Abi-Dargham et al, 1998) . Average reductions in [ Oswald et al, 2005) are approximately 13% for VST, 6% for CAU, and 11% for PUT. A study performed at our PET Centre using a similar dose of oral d-amphetamine and the same post-intake scanning interval found reductions of 13% in striatal [ 11 C]raclopride BPs (Cardenas et al, 2004) . However, this latter study reported considerably higher serum d-amphetamine levels and it used a different PET scanning system. A recent study using a similar dose of oral d-amphetamine and the antagonist D 2/3 radioligand [ 18 F]fallypride found reductions of 5.6, 11.2, and 6.6% in CAU, PUT, and VST, respectively (Riccardi et al, 2006) , reductions that are sensibly smaller than the 13.2, 20.8, and 24.9% reductions found in these corresponding structures with [ , and direct comparisons between [
11 C]NPA and [
11 C]-( + )-PHNO show that the latter ligand is more sensitive to endogenous dopamine than the former one . Somewhat in contrast to these findings are results obtained in rats (Wilson et al, 2005) that show maximal reductions of 38% in [ A peculiarity of [ 11 C]-( + )-PHNO PET is the high BPs measured in GP. Tracer kinetics in GP proved to be different from those in neo-striatal regions, and no significant post-amphetamine reductions were found in the GP. Peak-uptake in GP was lower than in VST, CAU or PUT, and radioligand-washout considerably slower (Figure 1 ). Since equilibrium is reached later in the GP and since it is more sustained, activity measured in GP throughout the later part of the scanning session contributes substantially more to BP measures derived with SRTM than late-scan activity in neo-striatal ROIs . As a direct consequence, the more noisy late parts of TACs increase variability of BP measurements in the GP. As shown in Figure 1 , peak uptake in VST was slightly lower than in CAU and PUT. Although not to the extent seen in GP, tracer washout from VST seemed to be relatively slow, leading to a more extended equilibrium with greater weight of the late, more 'noisy' parts of the TACs in VST as well. This might explain in part the high variability observed in GP and VST, and it may have contributed to the lack of significant post-d-amphetamine reductions in the GP. On the other hand, three individuals with very low d-amphetamine levels showed an increase rather than a decrease in post-d-amphetamine [
11 C]-( + )-PHNO BPs in GP ( Figure 2 ). As seen easily in Figure 3 , this increase contributed substantially to the highly significant correlation between serum d-amphetamine-levels and [ Gurevich and Joyce, 1999; Murray et al, 1994) , is compatible with a significant contribution of D 3 receptors to the captured signal. Second, some studies point towards a higher in vitro (Freedman et al, 1994) and in vivo (Narendran et al, 2006) high is considerably higher than the affinity for D 3 receptors (Seeman et al, 2005) , and in contrast to pretreatment with the partial D 3 receptor agonist BP897 in baboons (Narendran et al, 2006) , pre-treatment with the D 3 antagonist SB-277011 did not significantly reduce [ 11 C]-( + )-PHNO binding in the cat striatum . However, reductions in [ 11 C]-( + )-PHNO BPs after d-amphetamine in this study were largest in VST, but smallest in GP. It is thus unlikely that binding to D 3 receptors alone accounts for both observations. Other factors, such as regional differences in the amount of dopamine released, should be considered in the interpretation of this finding. In sum, while not conclusive so far, evidence points to an important contribution of D 3 receptor binding to the high BPs measured in GP.
Although competitive inhibition of radioligand binding is the hypothesis most commonly put forward to explain reductions in radioligand binding after d-amphetamine administration, several observations suggest that other mechanisms such as receptor internalization (Sun et al, 2003) or changes in receptor affinity (Ginovart et al, 2004) could contribute to this effect (for review see Ginovart, 2005; Laruelle, 2000) . It is thus a limitation of the present studyFas of all other competition studies performed with D 2/3 antagonist radioligands in humansFthat the methodology does not allow to identify the exact mechanism leading to decreased radioligand binding after d-amphetamine administration. Another limitation of the present study is that we did not apply correction for partial volume effects (PVEs). Since ROIs such as GP and VST are relatively small for resolutions reached by current PET scanning systems, and since they are adjacent to receptor-rich regions such as PUT, correction for PVEs can be expected to add to the reliability of d-amphetamine-induced BP changes in this regions. However, a recent study using [
11 C]raclopride showed that correction for PVEs resulted in higher estimates of the d-amphetamine effect in the VST of healthy subjects (Martinez et al, 2005) , suggesting that, if anything, we might have underestimated the actual d-amphetamine effects on [ Nausea and emesis are typical unwanted drug effects during treatment with dopamine agonists. Injected radioligand mass was by no means higher than what is usually administered in PET studies using antagonist radioligands. Still, the close temporal contiguity between tracer injection and nausea is suggestive for a pharmacological effect of [ 11 C]-( + )-PHNO, and, possibly owing to the presence of spare D 2 high states, some of the pharmacological effects of dopamine agonists, such as inhibition of prolactin secretion (Meller et al, 1991) , have been shown to occur at low receptor occupancies. According to the tracer principle, a radioligand should not perturb the biological system it is measuring. Although nausea might be interpreted as an indication that the tracer principle was violated in the present study, evidence suggests that this is unlikely to be the case. First, estimation of central receptor occupancy during [
11 C]-( + )-PHNO PET according to the method described by Hume et al (1998) results in a mean7SD occupancy of 1.670.5% when using an ED 50 value of 7.7 nmol/kg as measured in vivo in cats (Ginovart; unpublished observation) . This is similar to what has been described for [ 11 C]raclopride PET (Nordström et al, 1992) . Second, the ED 50 of ( + )-PHNO for inducing emesis in animal experiments is two orders of magnitude smaller than the ED 50 for inducing motor effects or stereotyped behavior (Martin et al, 1984) . Third, therapeutic ( + )-PHNO plasma levels, even at the low end, are at least three orders of magnitude higher than what is measured after a single injection of approximately 2 mg total tracer mass as used in our study (Coleman et al, 1990; Ginovart et al, 2006b ). Finally, ( + )-PHNO-induced emesis is readily prevented by pretreatment with peripherally acting dopamine receptor antagonists in animals (Martin et al, 1984; Nomoto et al, 1987) and humans (Grandas et al, 1987) . In sum, nausea is most likely a peripheral effect caused by even minute doses of ( + )-PHNO acting at dopamine receptors outside the blood brain barrier in the area postrema (Carpenter, 1990 ).
Pretreatment with a peripheral dopamine receptor antagonist may be a viable strategy to avoid [ 
